FitLife Brands, Inc. Form 8-K Summary
Business Context and Reporting Period
FitLife Brands, Inc. (FTLF) filed this Current Report on Form 8-K on October 10, 2023, to disclose material events occurring on that date. The company, incorporated in Nevada and trading on the Nasdaq Capital Market, operates in the nutrition and wellness sector.
Key Financial Metrics and Transactions
This filing details two primary financial events rather than periodic operating results:
- Debt Financing: The Company entered into a Second Amended and Restated Credit Agreement with First Citizens Bank, securing a Term B Loan of $10.0 million.
- Acquisition: The Company completed the acquisition of substantially all assets of MusclePharm Corporation for a total consideration of approximately $18.5 million.
- Liquidity and Funding: The acquisition was funded using $10.0 million from the new Term B Loan and the remainder from existing working capital. A cash payment of $16,680,904 was made on the closing date, inclusive of a prior deposit of $1,825,000.
Material Changes and Loan Terms
The filing outlines significant changes to the Company's capital structure and asset base:
- Loan Terms: The $10.0 million Term B Loan accrues interest at a rate of 2.75% above the one-month Term SOFR Rate. Principal and interest payments are due quarterly (March, June, September, December), commencing December 10, 2023, with full amortization required by October 10, 2028.
- Guarantees: The Company's subsidiaries (NDS Nutrition Products, Inc., iSatori, Inc., 1000374984 Ontario, Inc., and Mimi's Rock Corp.) reaffirmed their guaranty of the loan obligations.
- Asset Acquisition: The acquisition of MusclePharm assets was consummated pursuant to a Final Order from the United States Bankruptcy Court for the District of Nevada.
Outlook, Risks, and Management Commentary
Management announced the consummation of the acquisition via a press release on October 13, 2023. The filing includes standard legal disclaimers noting that representations and warranties in the loan documents are for the benefit of the contracting parties and may not reflect the current state of facts for investors. No specific forward-looking financial guidance or revenue projections were included in this specific filing.
Key Facts for Investor Verification
- Verify the impact of the $10.0 million debt obligation on the Company's future cash flow requirements, specifically the quarterly amortization schedule starting December 2023.
- Confirm the integration status and expected revenue contribution of the acquired MusclePharm assets.
- Review the full text of the Second Amended and Restated Credit Agreement (Exhibit 10.1) for specific covenants and potential default triggers.
- Assess the Company's remaining working capital position after funding the $6.68 million portion of the acquisition not covered by the new loan.